MedTrace Logo

A Clinical Trial to Investigate the Efficacy and Safety of a Plant-based Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain

NCT07695714 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-18

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate the efficacy and safety of plant-derived cetylated fatty acids (CFA) on joint health and mobility in adults with persistent knee pain. The main question it aims to answer is what is the change from baseline to day 42 in knee joint health, as assessed by the KOOS pain sub-scale scores, between plant-derived cetylated fatty acids (CFA) and placebo? Researchers will compare plant-derived cetylated fatty acids (CFA) with placebo to evaluate its effects on joint health, mobility, pain, and stiffness. Participants will be asked to:

* Consume plant-derived cetylated fatty acids (CFA) or placebo daily from Day 1 until the day before the end-of-study visit
* Have height, weight, heart rate, and blood pressure measurements taken
* Complete the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaire
* Complete the 6-Minute Walk Test (6MWT)
* Complete the 30 seconds chair sit to stand test
* Complete the pain and stiffness Likert scale
* Complete the subject treatment diary daily

Conditions

  • Joint Health
  • Mobility
  • Knee Pain

Interventions

DIETARY_SUPPLEMENT

Plant-derived cetylated fatty acids (CFA)

Participants will be instructed to take 4 softgels daily, starting on day 1 until the day before their end of study visit.

DIETARY_SUPPLEMENT

Placebo

Participants will be instructed to take 4 softgels daily, starting on day 1 until the day before their end of study visit.

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • Everwell Health

    lead INDUSTRY

Principal Investigators

  • David Crowley · KGK Science Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-02-28
Completion
2027-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07695714 on ClinicalTrials.gov